Citations

Clear

4847 citation(s) found for "Yu, Eric".

LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins
Wei, Wei‐Qi, Li, Xiaohui , Feng, QiPing , Kubo, Michiaki , Peissig, Peggy , Karlson, Elizabeth W. , Jarvik, Gail P. , Shang, Ning , Larson, Eric , Shaffer, Christian M., Maeda, Shiro , Horikoshi, Momoko , Ritchie, Marylyn D. , Larson, Eric B. , Crosslin, David R. , Bland, Harris T. , Pacheco, Jennifer A. , Rasmussen‐Torvik, Laura J. , Cox, Nancy J. , Wilke, Russell A. , Rotter, Jerome I. , Momozawa, Yukihide , Roden, Dan M. , Krauss, Ronald M. , Denny, Joshua C. , Denny, Joshua C , Bland, Sarah T , Jarvik, Gail P , Wei, Wei-Qi , Rotter, Jerome I , Pacheco, Jennifer A , Kullo, Iftikhar J. , Lee, Ming Ta Michael , Edwards, Todd L. , Mosley, Jonathan D , Williams, Marc S , Cronkite, David , Hripcsak, George , Stein, Christoph , Roden, Dan M. , Feng, Qiping , Rasmussen-Torvik, Laura J

Mayo Clinic

Circulation | April 27, 2018 | Volume: 138 | Issue: 17 | Pages: 1839-1849

10.1161/circulationaha.117.031356 | PMID 29703846 Get It

Background: Coronary heart disease (CHD) is a leading cause of death globally. Although therapy with statins decreases circulating levels of low-density lipoprotein cholesterol and the incidence of CHD, additional events occur despite statin therapy in some individuals. The genetic determinants of this residual cardiovascular risk remain unknown. Methods: We performed a 2-stage genome-wide association study of CHD events during statin therapy. We first identified 3099 cases who experienced CHD events (defined as acute myocardial infarction or the need for coronary revascularization) during statin therapy and 7681 controls without CHD events during comparable intensity and duration of statin therapy from 4 sites in the Electronic Medical Records and Genomics Network. We then sought replication of candidate variants in another 160 cases and 1112 controls from a fifth Electronic Medical Records and Genomics site, which joined the network after the initial genome-wide association study. Finally, we performed a phenome-wide association study for other traits linked to the most significant locus. Results: The meta-analysis identified 7 single nucleotide polymorphisms at a genome-wide level of significance within the LPA/PLG locus associated with CHD events on statin treatment. The most significant association was for an intronic single nucleotide polymorphism within LPA/PLG (rs10455872; minor allele frequency, 0.069; odds ratio, 1.58; 95% confidence interval, 1.35–1.86; P =2.6×10 − 10 ). In the replication cohort, rs10455872 was also associated with CHD events (odds ratio, 1.71; 95% confidence interval, 1.14–2.57; P =0.009). The association of this single nucleotide polymorphism with CHD events was independent of statin-induced change in low-density lipoprotein cholesterol (odds ratio, 1.62; 95% confidence interval, 1.17–2.24; P =0.004) and persisted in individuals with low-density lipoprotein cholesterol ≤70 mg/dL (odds ratio, 2.43; 95% confidence interval, 1.18–4.75; P =0.015). A phenome-wide association study supported the effect of this region on coronary heart disease and did not identify noncardiovascular phenotypes. Conclusions: Genetic variations at the LPA locus are associated with CHD events during statin therapy independently of the extent of low-density lipoprotein cholesterol lowering. This finding provides support for exploring strategies targeting circulating concentrations of lipoprotein(a) to reduce CHD events in patients receiving statins.
0521 Perioperative Positive Airway Pressure Compliance in Obstructive Sleep Apnea Patients
Anders, G, Olson, Eric J.

Mayo Clinic

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A195-A195

10.1093/sleep/zsy061.520 Get It

1056 Exploring the Impact of a Sleep Enhancement Program in the Inpatient Environment on Patient Satisfaction: Lessons Learned
Moore, Wendy , Stellpflug, C, Ashbeck, R, Cutshall, S, Klevin, K, Marsh, Shona, Olson, Eric J. , Stellpflug, Courtney, Ashbeck, Rebecca, Marsh, S, Morgenthaler, Timothy I. , Lim, Kaiser G.

Mayo Clinic

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A393-A393

10.1093/sleep/zsy061.1055 Get It

Influence of the Vibralung Acoustical Percussor on pulmonary function and sputum expectoration in individuals with cystic fibrosis
Wheatley, Courtney M. , Baker, Sarah E. , Daines, C, Phan, Hanna , Martínez, Marina González, Snyder, Eric M., Wheatley-Guy, Courtney M , Morgan, Wayne J. , Baker, Sarah E

Mayo Clinic

Therapeutic Advances in Respiratory Disease | April 26, 2018 | Volume: 12 | Issue: No issue available | Pages: No page available

10.1177/1753466618770997 | PMID 29697011 Get It

Background: The Vibralung Acoustical Percussor is a new airway clearance therapy (ACT) utilizing intrapulmonary sound waves in addition to positive expiratory pressure (PEP). We evaluated the safety of the Vibralung and collected preliminary data on its ability to mediate sputum expectoration in individuals with cystic fibrosis (CF). Methods: Over two separate studies, 10 and 11 mild to moderate CF patients were recruited for study I and II, respectively. Study I: Vibralung was used for 20 min with either no sound (NS: PEP only) or sound (S: PEP and sound) on randomized visits. Pulmonary function, diffusion capacity of the lungs for carbon monoxide and nitric oxide (DLCO/DLNO), symptoms, and peripheral oxygen saturation (SpO2) were measured at baseline and at 1 and 4 h post treatment. Expectorated sputum was collected over 4 h post treatment. Study II: over 5 days of in-hospital therapy, the Vibralung or vibratory vest therapy (Vest) were used for two therapy sessions per day, with sputum collected for 20 min following each therapy and pulmonary function accessed pre and post each 5-day period (days 1–5 or 7–11) in a randomized crossover design. Results: Vibralung usage resulted in no change from baseline to 4 h post in pulmonary function, SpO2 or symptoms ( p > 0.05). At 4 h post therapy, the DLCO- and DLNO-derived measure of alveolar–capillary unit function (DM/ VC) showed improvement (DM/ VC = 12.5 ± 5.5 versus 7.3 ± 18.8% change, S versus NS) with no difference between S and NS ( p = 0.74). Sputum expectoration was similar between S and NS conditions (wet sputum = 10.5 ± 4.6 versus 9.9 ± 3.2 g, S versus NS, p = 0.25). There were no differences in the improvement in pulmonary function between Vibralung and Vest during either 5-day period during the hospital stay. Conclusions: Vibralung was well tolerated and caused no detrimental changes in pulmonary function metrics. The Vibralung appears to be a safe ACT in individuals with CF.
Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group
Kossoff, Eric H. , Zupec‐Kania, Beth, Auvin, Stéphane , Ballaban‐Gil, Karen , Bergqvist, Anna, Blackford, Robyn, Buchhalter, Jeffrey , Caraballo, Roberto , Cross, J. Helen , Dahlin, Maria , Donner, Elizabeth , Güzel, Orkide, Jehle, Rana, Klepper, Joerg , Kang, Hoon‐Chul , Lambrechts, Danielle A.J.E. , Liu, Y.M. Christiana, Nathan, Janak , Pfeifer, Heidi H., Rho, Jong M. , Scheffer, Ingrid E. , Sharma, Suvasini , Stafstrom, Carl E. , Thiele, Elizabeth A. , Turner, Zahava , Vaccarezza, María, Louw, Elles van der , Friends, Matthew's, Caraballo, Roberto H , Wirrell, Elaine C., Auvin, Stéphane , Cross, Helen J , Scheffer, Ingrid E , Nordli, Douglas R. , Veggiotti, Pierangelo , Wheless, James W. , Wirrell, Elaine , Friends, Matthew's

Mayo Clinic

Epilepsia Open | April 25, 2018 | Volume: 3 | Issue: 2 | Pages: 175-192

10.1002/epi4.12225 | PMID 29881797 Get It

Summary Ketogenic dietary therapies ( KDTs ) are established, effective nonpharmacologic treatments for intractable childhood epilepsy. For many years KDTs were implemented differently throughout the world due to lack of consistent protocols. In 2009, an expert consensus guideline for the management of children on KDT was published, focusing on topics of patient selection, pre‐ KDT counseling and evaluation, diet choice and attributes, implementation, supplementation, follow‐up, side events, and KDT discontinuation. It has been helpful in outlining a state‐of‐the‐art protocol, standardizing KDT for multicenter clinical trials, and identifying areas of controversy and uncertainty for future research. Now one decade later, the organizers and authors of this guideline present a revised version with additional authors, in order to include recent research, especially regarding other dietary treatments, clarifying indications for use, side effects during initiation and ongoing use, value of supplements, and methods of KDT discontinuation. In addition, authors completed a survey of their institution's practices, which was compared to responses from the original consensus survey, to show trends in management over the last 10 years.
Novel Arthroscopic Tendon Transfers for Posterosuperior Rotator Cuff Tears
Wagner, Eric R. , Welp, Kathryn M., Elhassan, Bassem T. , Higgins, Laurence D. , Warner, Jon J.P. , Warner, Jon J P , Wagner, Eric R , Woodmass, Jarret Murray , Chang, Michelle J.

Mayo Clinic

JBJS Essential Surgical Techniques | April 24, 2018 | Volume: 8 | Issue: 2 | Pages: e12

10.2106/jbjs.st.17.00062 | PMID 30233984 Get It

Background: Massive irreparable rotator cuff tears in both the primary and the revision setting are challenging problems. There remains controversy over the ideal treatment methods for these patients. In the case of an irreparable posterosuperior rotator cuff tear, tendon transfers 1–12 have emerged as a reliable option, with a durable outcome. The most commonly used tendon transfer options are the latissimus dorsi (LD) 1–6 and the lower trapezius (LT) 12 . Description: The LD transfer is performed by first harvesting the LT tendon from the humeral shaft. It is critical to release the many adhesions to the muscle belly as well as to separate it from the teres major muscle. The tendon is then transferred intra-articularly, in an interval between the deltoid and the teres minor. The tendon is anchored arthroscopically after preparation of the anterolateral aspect of the tuberosity. The LT transfer is performed by harvesting the LT muscle and tendon off its insertion on the medial aspect of the scapular spine. It should be mobilized to maximize excursion by releasing adhesions. An Achilles tendon allograft is anchored into the anterior aspect of the greater tuberosity arthroscopically. The Achilles tendon is then secured to the LT tendon. Alternatives: In addition to tendon transfer, options include: Partial or complete attempted repair 13–17 . Augmentation or bridging with allografts 18–23 . Superior capsular reconstruction 24 . Subacromial balloon 25 . Rationale: There remains a paucity of literature comparing tendon transfers with alternatives. However, when considering a tendon transfer, certain principles are critical in order to achieve an optimal outcome: The recipient and transferred tendons must have similar musculotendinous excursion. The recipient and transferred tendons should have similar lines of pull. One tendon (the transferred) should be designed to replace 1 function (of the recipient). The function of the transferred tendon and muscle should be expendable without substantial donor site morbidity. The strength of the transferred muscle must be at least grade 4. When deciding between the LT and LD transfer, certain considerations should be taken into account. The LD transfer has a proven history of successfully treating massive irreparable posterosuperior rotator cuff tears in studies with long-term follow-up 1–6 . Alternatively, although the LT transfer has only recently gained popularity, it has the advantage of “in-phase” muscle function, since the trapezius naturally contracts during shoulder external rotation. Furthermore, its line of pull almost completely mimics the infraspinatus.
Developing Interventional Radiology Anticoagulation Guidelines: Process and Benefits †
Osborn, Howard H., Naidu, Sailen G., Huettl, Eric A., Kriegshauser, J. Scott , Naidu, Sailendra , Patel, Maitray D.

Mayo Clinic

Journal of Clinical Medicine | April 23, 2018 | Volume: 7 | Issue: 4 | Pages: 85

10.3390/jcm7040085 | PMID 29677117 Get It

We created, posted, and updated radiology department anticoagulation guidelines and identified various steps in the process, including triggering events, consensus building, legal analysis, education, and distribution of the guidelines to nurses and clinicians. Supporting data collected retrospectively, before and after implementation, included nursing satisfaction survey results and the number of procedure cancellations. After the guidelines were developed and posted, significantly fewer procedures were cancelled, nursing satisfaction was higher, and radiologists performed procedures with less variability. Anecdotally, radiologists had fewer queries about anticoagulation. The development and dissemination of radiologic procedure anticoagulation guidelines should be considered as a departmental quality improvement project.
Repeat-Associated Non-ATG (RAN) Translation in Fuchs' Endothelial Corneal Dystrophy
Soragni, Elisabetta , Petrosyan, Lina, Rinkoski, Tommy A. , Wieben, Eric D. , Baratz, Keith H. , Fautsch, Michael P. , Gottesfeld, Joel M.

Mayo Clinic

Investigative Opthalmology & Visual Science | April 20, 2018 | Volume: 59 | Issue: 5 | Pages: 1888

10.1167/iovs.17-23265 | PMID 29677349 Get It

Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation
O’Brien, Emily C. , Holmes, DaJuanicia N. , Thomas, Laine , Kowey, Peter R. , Singer, Daniel E. , Ezekowitz, Michael D. , Ansell, Jack , Go, Alan S. , Reiffel, James A. , Piccini, Jonathan P. , Fonarow, Gregg C. , Allen, Larry A. , Gersh, Bernard J. , Naccarelli, Gerald V. , Chan, Paul S. , Mahaffey, Kenneth W. , Freeman, James V. , Peterson, Eric D. , Hylek, Elaine M.

Mayo Clinic

Circulation | April 20, 2018 | Volume: 138 | Issue: 9 | Pages: 889-897

10.1161/circulationaha.117.031354 | PMID 29678813 Get It

Background: Bleeding is commonly cited as a reason for stopping oral anticoagulants (OACs). Whether minor bleeding events (nuisance bleeding, NB) in patients with atrial fibrillation on OACs are associated with OAC discontinuation, major bleeding, and stroke/systemic embolism (SSE) is unknown. Methods: Within the ORBIT-AF prospective, outpatient registry (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation), we identified 6771 patients ≥18 years of age at 172 sites with atrial fibrillation and eligible follow-up visits. NB was ascertained from the medical record and was defined as minor bleeding that did not require medical attention (eg, bruising, hemorrhoidal bleeding). We used multivariable pooled logistic regression modeling to evaluate the associations between NB and major bleeding and SSE in the 180 days after documentation of NB. Our unit of analysis was the patient visit, occurring at ≈6-month intervals for a median of 1.5 years following enrollment. Changes in anticoagulation treatment satisfaction after NB were examined descriptively in a subset of patients. Results: The median age of the overall population was 75.0 (interquartile range, 67.0–81.0); 90.0% were white and 42.5% were female. Among 6771 patients (18 560 visits), n=1357 (20.0%) had documented NB, for an incidence rate of 14.8 events per 100 person-years. Over 96.4% of patients remained on OAC therapy after the NB event. Overall, 287 (4.3%) patients experienced major bleeding and 64 (0.96%) had a SSE event during follow-up. NB was not associated with a significant increased risk of major bleeding over 6 months in models adjusting for the ATRIA bleeding score (Anticoagulation and Risk Factors in Atrial Fibrillation) (odds ratio, 1.04; 95% confidence interval, 0.68–1.60; P =0.86). NB was also not associated with increased SSE risk over 6 months in models adjusting for the CHA 2 DS 2 -VASc risk score (odds ratio, 1.24; 95% confidence interval, 0.53–2.91; P =0.62). Conclusions: NB is common among patients with atrial fibrillation on OACs. However, NB was not associated with a higher risk of major bleeding or SSE over the next 6 months, suggesting its occurrence should not lead to changes in anticoagulation treatment strategies in OAC-treated patients. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01165710.
Empowering genomic medicine by establishing critical sequencing result data flows: the eMERGE example
Aronson, Samuel , Babb, Lawrence , Ames, Darren C., Gibbs, Richard A. , Connelly, John, Marsolo, Keith , Hartzler, Andrea L. , Liang, Wayne H. , Ralston, James D. , Devine, Emily Beth , Murphy, Shawn N. , Freimuth, Robert R. , Rasmussen, Luke V. , Peterson, Josh F. , Robinson, Jamie R. , Wiley, Ken, Taylor, Casey Overby , Group, eMERGE Network EHRI Working, Caraballo, Pedro J. , Babb, Lawrence , Rasmussen, Luke V , Freimuth, Robert R , Venner, Eric , Weng, Chunhua , Williams, Marc S , Chute, Christopher G. , Kullo, Iftikhar J. , Wehbe, Firas , Group, eMERGE Network EHRI Working, Peterson, Josh F

Mayo Clinic

Journal of the American Medical Informatics Association | April 19, 2018 | Volume: 25 | Issue: 10 | Pages: 1375-1381

10.1093/jamia/ocy051 | PMID 29860405 Get It

AbstractThe eMERGE Network is establishing methods for electronic transmittal of patient genetic test results from laboratories to healthcare providers across organizational boundaries. We surveyed the capabilities and needs of different network participants, established a common transfer format, and implemented transfer mechanisms based on this format. The interfaces we created are examples of the connectivity that must be instantiated before electronic genetic and genomic clinical decision support can be effectively built at the point of care. This work serves as a case example for both standards bodies and other organizations working to build the infrastructure required to provide better electronic clinical decision support for clinicians.